NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP 50 Pharmas » Sanofi-Aventis  1    
found files: 17
Sanofi-Aventis »15/09/2007 [Company watch]
Sanofi taps into Chinese cancer stem-cell know-how

Sanofi-Aventis has signed a research collaboration agreement with a Chinese institute in the cancer stem-cell field, becoming the latest big drugmaker to tap into China's growing life science skills...   more»

Sanofi-Aventis »02/11/2007 [Industry news]
Sanofi Pasteur wins Flu Vaccine contract for Beijing

In October Beijing released the 2007 tendering results for influenza vaccine, marking the first time the vaccine has been included in Beijing's reimbursement system. Sanofi Pasteur will supply 1.2 million doses of the influenza vaccine, an amount that should generate RMB 48 million for the company. Four domestic manufacturers, Sinovac, Jiangsu Yanshen, Zhejiang Tianyuan, and Dalian Yalifeng, will provide the remaining 1.6 million doses. Five additional manufacturers, Changchun Changsheng, Shanghai Institute of Biological Products, Berna, GSK, and Novartis, also took part in the bidding but were not selected to provide the drug. In September, Beijing announced that it would purchase 2.8 million doses of the influenza vaccine for approximately RMB 100 million to provide free flu vaccinations for Beijing citizens over 60 years of age and to subsidize vaccinations for schoolchildren. Vaccines from Sanofi Pasteur with a tendering price of RMB 40 will be used to vaccinate schoolchildren and charged at RMB 20. Vaccines from four domestic producers with a tendering price of RMB 34 will be provided free to Beijing's senior citizens. The influenza vaccine is a Class II vaccine in China and therefore is not covered by the national government reimbursement system....   more»

Sanofi-Aventis »29/11/2007 [Company watch]
Flu vaccine plant in Shenzhen biggest drug JV in China

The flu vaccine plant to be built in Shenzhen, agreed in a deal signed Monday between China and France's Sanofi-Aventis Group, will be the largest investment ever by a foreign drug maker in China. The 700-million-yuan (95.5-million U.S. dollars) plant will be built at the National Biological Industrial Base in Shenzhen's Longgang Grand Industrial Zone. The factory, to be run by Sanofi-Pasteur, the vaccine division of Europe's largest pharmaceuticals company Sanofi-Aventis, is expected to commence in early 2008. It would produce 25 million doses annually once production begins in 2012. By then, Shenzhen is expected to become China's - even Asia's - biggest vaccine manufacturing base....   more»

Sanofi-Aventis »03/04/2008 [Company watch]
Sanofi seeks partnerships in China

Dr. Marc Cuzel, head of R&D for Sanofi-Aventis , said that Sanofi would seek to establish half a dozen research partnerships with China universities and state-sponsored research institutions . This initiative will take the place of building its own research center in China. Sanofi believes that China is a good place to do research, but it already has so much innovation, Sanofi believes partnerships are a better way of taking advantage of China’s research capabilities. Sanofi will seek research in cancer and rheumatoid arthritis, he said....   more»

Sanofi-Aventis »12/05/2008 [Company watch]
Sanofi-Aventis patent revoked in latest IP wrangle twist

The State Intellectual Property Office (SIPO) has invalidated the Chinese patent for France-based Sanofi-Aventis' anti-tumor drug, docetaxel, following a patent dispute with Jiangsu Hengrui Medicine Co. Ltd., the Chinese company announced last week. In September last year, Sanofi-Aventis filed a suit with the Beijing High Court alleging that Hengrui Medicine infringed its patent for docetaxel. The company is seeking a total of RMB 95.20 million ($14.36 million) in damages from Hengrui Medicine. Hengrui Medicine responded by applying to SIPO to revoke the company's patent. Liu Guiming, director of the SIPO's Patent Office declined to explain on what grounds the patent was withdrawn, "Because the case has not been finalized yet". "Sanofi-Aventis will probably appeal to the Beijing No. 1 Intermediate Court to get the patent reinstated, after which, the two companies will continue the infringement suit in the high court," Wang Bin, an intellectual property law consultant with the Shanghai Municipal Food and Drug Administration's Scientific and Technical Information Institute, told Interfax today. Sanofi-Aventis has three months to appeal the decision by SIPA. Yi Hui, a Sanofi-Aventis public relations official said today that the company is "now collecting the relevant documents [to appeal]." Dai Hongbin, board director of Hengrui Medicine, explained to Intefax Hengrui Medicine's position. "We started to market the drug in 2003. The patent application record shows that while Sanofi-Aventis first applied for a patent in 2001, the patent was not approved until 2006," he said. Dai said that Hengrui Medicine will not back down. "Hengrui Medicine has other new products which are set to become new growth points. Losing the case will not affect the company's financial performance overly, unless it is forced to pay a huge amount of compensation," Hao Jianjie, a pharmaceutical analyst with TX Investment Co. Ltd., said. "This will obviously be another lengthy patent tussle between a Chinese company and a foreign company in China," Wang said, noting the similarity to the ongoing battle by Pfizer over Viagra patent infringements in China. Hao concurred, explaining that it is not uncommon for a foreign company to pursue lengthy patent wars against Chinese companies, which do not usually have the financial means to put up an extended fight. Docetaxel, a cytotoxic injection mainly used in the treatment of breast, ovarian and non-small-cell lung cancer, makes up a key part of Hengrui Medicine's anti-tumor drug sales. By taking advantage of lower production costs in China, the company has been able to offer the drug at a lower price than Sanofi-Aventis....   more»

Sanofi-Aventis »16/06/2008 [Company watch]
Sanofi Pasteur to donate 60 million doses of H5N1 Vaccine to WHO

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization (WHO) over 3 years for the establishment of an H5N1 vaccine global stockpile. Mr Wayne Pisano, President and Chief Executive Officer of sanofi Pasteur, said, “The H5N1 virus is currently circulating in some of the poorest regions of the world and an outbreak of pandemic influenza would most likely hit populations living in areas with limited access to vaccines. This donation of H5N1 vaccine aims to address the needs of those most vulnerable populations." "In addition to supporting the efforts of governments, it is essential that industry collaborates with international organizations such as WHO, the Bill and Melinda Gates Foundation and other global health players. This is the best way to build a stockpile of vaccines for developing nations, ready to be deployed on the ground in the event of a pandemic flu outbreak," added Mr Pisano. Each year since 2004, sanofi pasteur produced millions of doses of H5N1 avian influenza vaccine, both in France and in the United States. In April 2007, the US Food and Drug Administration (FDA) licensed sanofi pasteur's H5N1 vaccine, the first avian influenza vaccine for humans in the US. Sanofi Pasteur recently conducted clinical trials with a novel, proprietary adjuvant aimed at dramatically reducing the amount of antigen needed to elicit a protective immune response to the H5N1 strain currently identified by global health authorities and experts as a potential source for the next pandemic. These data show the ability of this new investigational H5N1 pandemic influenza vaccine to generate a high immune response with a very low dose of H5N1 antigen. Sanofi Pasteur is committed to producing as many doses as possible of its most advanced vaccine in the shortest possible timeframe should a pandemic be declared by WHO. Under such circumstances, sanofi pasteur's seasonal influenza vaccine facilities would globally be able to switch to pandemic vaccine manufacturing. Sanofi Pasteur recently completed the construction of a new influenza vaccine manufacturing facility in the United States. This new facility is planned to go online in 2009. Sanofi Pasteur is also on track to build a facility to manufacture seasonal influenza vaccine in China for the local market. This vaccine manufacturing facility is due to be operational by 2012. A new formulation and filling facility located in France is also planned to become operational in 2009. This new state-of-the-industry facility will boost sanofi pasteur's filling capabilities. With the production of 180-million doses of seasonal influenza vaccine last year, sanofi pasteur confirmed its leadership by supplying an estimated 40 percent of the world influenza vaccine marke...   more»

Sanofi-Aventis »29/07/2008 [Company watch]
Sanofi Anentis Extends Collaboration in China

NovaMed Pharmaceuticals Inc, a leading China-based pharmaceutical company which provides outsourced drug development and commercialization services for global multinational pharmaceutical and biotechnology companies today announced that their collaboration with sanofi-aventis in China has been extended, beginning July 2008. In addition to the exclusive outsourcing of five other established sanofi-aventis China drugs in China, NovaMed is now also charged with the promotion and distribution of Depakine®, the treatment of choice for epilepsy worldwide since the 1970s. Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China, marks the sixth sanofi-aventis product for NovaMed to commercialize in China. The world leading pharmaceutical company, No. 1 in Europe, sanofi-aventis was the first to partner with NovaMed in China after its foundation in 2006, for the outsourcing of a series of central nervous system (CNS), cardiovascular and urology products. The ongoing collaborative relationship between the two companies began in 2006 with Xatral®, the first product in a class of alpha1-blockers to treat benign prostatic hyperplasia (BPH). A recent IMS Health report revealed that Xatral® has demonstrated very strong growth, notably at the highest rate in the BPH treatment market since the cooperation with NovaMed began. The focus on collaboration with multinational pharmaceutical companies in China underscores the opportunity for NovaMed to expand hospital coverage in various cities across China and facilitate greater patient access to clinically proven and effective therapies. NovaMed is now the exclusive promotion partner of three sanofi-aventis CNS products in China, including Depakine®, Stilnox® and Perenan®. In addition, it is sanofi-aventis China’s appointed outsourcing partner for Tritace® (cardiovascular), Xatral®(urology), and Rulide® (Infection). Tritace® is one of the leading treatment options for hypertension and high risk cardiovascular patients in the market and Stilnox® is the most widely prescribed hypnotic in the US for improving the continuity and quality of sleep. The collaboration with sanofi-aventis with Depakine allows NovaMed to continue to strengthen its sales and marketing efforts in the CNS pipeline. The company’s sales and marketing team is currently over 350 people strong across China and includes a special oncology business unit of 55 people....   more»

Sanofi-Aventis »15/10/2008 [Company watch]
Sanofi cuts ribbon on Shenzhen vaccine plant

Sanofi-Aventis held an opening ceremony October 12 for the completed phase I construction of its vaccine plant in Shenzhen. The new plant is expected to be running at full steam by 2012 with an output capacity of 2.5 million doses of seasonal influenza vaccine per year. Sanofi Pasteur, the vaccines division of Sanofi-Aventis, began construction of the plant, a total scheduled investment of RMB 670 million, in the beginning of 2008. According to Wayne Pisano, president and CEO of Sanofi Pasteur, the rate of vaccination for influenza is only 2%, much lower than the 20% and 40% rate in Europe and North America....   more»

Sanofi-Aventis »21/10/2008
Sanofi-Aventis expands its R&D presence in China

Sanofi-aventis announced today the strengthening of its R&D presence in China, with the expansion of its R&D facility in Shanghai, the new establishment of a state-of-the-art Biometrics Center in Beijing, and the signature of a partnership agreement with the Shanghai Institutes for Biological Sciences (SIBS) for the discovery of breakthrough drugs for neurological diseases, diabetes, and cancer....   more»

Sanofi-Aventis »23/04/2009 [Company watch]
Sanofi sees acquisition opportunities in China-CEO

(Reuters) - Sanofi-Aventis SA , the world\'s fourth-biggest drug maker, is seeking acquisition opportunities in China where the government has vowed to beef up its long-neglected public health care system, its chief executive Chris Viehbacher said on Thursday....   more»

Sanofi-Aventis »21/04/2009 [Company watch]
Sanofi-aventis Announces New Investment in China to Locally Produce Lantus® SoloSTAR®

French Group Committed to Partnering with the Chinese Diabetes Society to Undertake in China the World’s Largest Diabetes Genotyping Project...   more»

»12/10/2009 [Company watch]
Merial Invests $70 Million in Nanchang, China

Merial, the Animal Health division of the sanofi-aventis Group, announced today that Merial Animal Health Co. (China) held a ground-breaking ceremony for an expansion project at its plant located in the Nanchang Hi-tech Development Zone, China. Merial Animal Health Co. (China), a venture of Merial Limited and the Group\'s first production facility in China has been in operation for almost 20 years....   more»

Sanofi-Aventis »30/10/2009 [Company watch]
Sanofi-Aventis enters China’s OTC market

Sanofi-Aventis has signed a joint venture agreement with Minsheng Pharmaceutical Group of Hangzhou to exploit the country’s booming OTC vitamin and mineral market. China’s OTC market is predicted to become the world\'s second largest OTC market in 2010, according to Olivier Charmeil, Sanofi-Aventis\' senior vice president for pharmaceutical operations in Asia/Pacific and Japan....   more»

Sanofi-Aventis »01/02/2010 [Industry news]
Sanofi, Minsheng in consumer healthcare deal

French drug giant Sanofi-aventis has signed an agreement with Minsheng Pharmaceutical of China to form a new consumer healthcare joint venture....   more»

Sanofi-Aventis »05/03/2010 [Company watch]
Sanofi-Aventis Looks for More China Partnerships

Sanofi-Aventis (NYSE: SNY) wants to continue building its presence in China. Company officials said Sanofi-Aventis will seek additional partnerships following the joint venture announced last month with Minsheng Pharmaceutical, a JV that will develop vitamin and mineral products in the consumer healthcare sector. Sanofi has gone on record to say it prefers the partnership approach in China, as opposed to building its own R&D center....   more»

»12/04/2010 [Industry news]
Sanofi Aventis opens regional R&D centre in Shanghai

French pharma giant Sanofi-Aventis has launched its first regional research and development centre in Shanghai in China....   more»

Sanofi-Aventis »22/04/2010 [Company watch]
Sanofi Aventis: Deeply Committed to China

Sanofi-Aventis (NYSE: SNY) recently announced it has established a regional R&D center in Shanghai. Unlike many of its big pharma competitors, Sanofi-Aventis is not building a lab and hiring scores of scientists to work exclusively on S-A projects. Instead, the company is focused on developing collaborations, a strategy that allows it to build on China’s innovative biopharma culture....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.